Filing Details
- Accession Number:
- 0001415889-23-011677
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-08-01 18:00:14
- Reporting Period:
- 2023-07-28
- Accepted Time:
- 2023-08-01 18:00:14
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1798749 | Aerovate Therapeutics Inc. | AVTE | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1185035 | P Timothy Noyes | C/O Aerovate Therapeutics, Inc. 930 Winter Street, Suite M-500 Waltham MA 02451 | Chief Executive Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-07-28 | 5,478 | $2.14 | 5,478 | No | 4 | M | Direct | |
Common Stock | Disposition | 2023-07-28 | 5,478 | $18.00 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2023-07-28 | 5,478 | $0.00 | 5,478 | $2.14 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
383,381 | 2031-04-01 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022.
- A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.